|
[Related PubMed/MEDLINE]
Total Number of Papers: 169
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: IVIVE |
| Long Form |
: in vitro-in vivo extrapolation |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
Quantitative Interpretation of ToxTracker Dose Response Data for Potency Comparisons and Mode-of-Action Determination. |
AED, BMD, PCA |
| 2 |
2023 |
[In vitro in vivo extrapolation (IVIVE) in safety pharmacology to improve human predictability -new evaluation systems for new drug modalities]. |
--- |
| 3 |
2022 |
A weight of evidence approach for bioaccumulation assessment. |
BAFs, BAT, BCF, beta-HCH, BMF, DETs, HCB, LOE, QSARs, SETAC, TMFs, WoE |
| 4 |
2022 |
Analysis of Time-Dependent Pharmacokinetics Using In Vitro-In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling. |
PBPK, TDPK |
| 5 |
2022 |
Cabozantinib Carries the Risk of Drug-Drug Interactions via Inhibition of UDPglucuronosyltransferase (UGT) 1A9. |
DDIs, TKI, UGT |
| 6 |
2022 |
Comprehensive interpretation of in vitro micronucleus test results for 292 chemicals: from hazard identification to risk assessment application. |
AEDs, BER, BMC, PODs |
| 7 |
2022 |
DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data. |
ADME, PBPK |
| 8 |
2022 |
Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5'-Diphosphate Glucuronosyltransferase. |
PBPK, UGTs |
| 9 |
2022 |
Exposure forecasting - ExpoCast - for data-poor chemicals in commerce and the environment. |
EPA |
| 10 |
2022 |
In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species. |
ECCS, HEPs, LMs, SFs |
| 11 |
2022 |
In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms. |
COMT, DDIs, UGTs |
| 12 |
2022 |
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. |
BBB, CNS, PBPK |
| 13 |
2022 |
Potential herb-drug interaction risk of thymoquinone and phenytoin. |
CYP2C9 |
| 14 |
2022 |
The Environmental Pollutant Bromophenols Interfere With Sulfotransferase That Mediates Endocrine Hormones. |
BPs, Ki, PNP |
| 15 |
2022 |
Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. |
GMP, NAMs, PBK, QIVIVE |
| 16 |
2022 |
Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells. |
MATE1, OCT2, PBPK, TOR |
| 17 |
2022 |
Validation of Methods for in Vitro-in Vivo Extrapolation Using Hepatic Clearance Measurements in Isolated Perfused Fish Livers. |
--- |
| 18 |
2021 |
A comprehensive review on non-clinical methods to study transfer of medication into breast milk - A contribution from the ConcePTION project. |
PBPK |
| 19 |
2021 |
A New Guidance for the Prediction of Hepatic Clearance in the Early Drug Discovery and Development from the in Vitro-to-in Vivo Extrapolation Method and an Approach for Exploring Whether an Albumin-Mediated Hepatic Uptake Phenomenon Could be Present Under in Vivo Conditions. |
ALB, CL |
| 20 |
2021 |
An integrated exposure and pharmacokinetic modeling framework for assessing population-scale risks of phthalates and their substitutes. |
DEHA, DEHP, DEP, DINCH, DPHP |
| 21 |
2021 |
Can In Vitro-In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. |
--- |
| 22 |
2021 |
Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. |
CPPGL, MPPGL, PBPK |
| 23 |
2021 |
High-throughput PBTK models for in vitro to in vivo extrapolation. |
HTS, HTTK, PBTK, TK |
| 24 |
2021 |
In vitro enantioselective inhibition of the main human CYP450 enzymes involved in drug metabolism by the chiral pesticide tebuconazole. |
CYP450, TEB |
| 25 |
2021 |
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs. |
PK, TK |
| 26 |
2021 |
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates. |
DDIs, PBPK, UGTs |
| 27 |
2021 |
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. |
DCE, MRI, MRP2, OATP1B1, PBPK, tDDI |
| 28 |
2021 |
Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition. |
DDIs, PBPK |
| 29 |
2021 |
Prediction of Drug Clearance from Enzyme and Transporter Kinetics. |
PBPK |
| 30 |
2021 |
Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling. |
BMC, DILI, NP-TCMs, PBPK, SVM |
| 31 |
2021 |
Prediction of Oral Pharmacokinetics Using a Combination of In Silico Descriptors and In Vitro ADME Properties. |
AUCp,oral, ESFs |
| 32 |
2021 |
Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. |
AUC, ChAT, PBPK |
| 33 |
2021 |
Quantitative In Vitro-to-In Vivo Extrapolation for Mixtures: A Case Study of Superfund Priority List Pesticides. |
--- |
| 34 |
2021 |
Quaternary Ammonium Compounds: Bioaccumulation Potentials in Humans and Levels in Blood before and during the Covid-19 Pandemic. |
QACs |
| 35 |
2020 |
Abundance and Associated Variations of Cytochrome P450 Drug-Metabolizing Enzymes in the Liver of East Asian Adults: A Meta-Analysis. |
PBPK |
| 36 |
2020 |
Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research. |
CL, CL, ESF, PSu,inf |
| 37 |
2020 |
Chemical concentrations in cell culture compartments (C5) - free concentrations. |
fu, NAM |
| 38 |
2020 |
Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. |
cfu,mic, ECCS, RBF, RF |
| 39 |
2020 |
Effect of Human Plasma on Hepatic Uptake of Organic Anion-Transporting Polypeptide 1B Substrates: Studies Using Transfected Cells and Primary Human Hepatocytes. |
HEK, OATP |
| 40 |
2020 |
Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. |
CL, LLV, LV |
| 41 |
2020 |
Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance. |
HH, HLM |
| 42 |
2020 |
Examining Uncertainty in In Vitro-In Vivo Extrapolation Applied in Fish Bioconcentration Models. |
BCFs |
| 43 |
2020 |
In vitro-in vivo extrapolation of hepatic and gastrointestinal biotransformation rates of hydrophobic chemicals in rainbow trout. |
BaP, EHMC, OCT, PYR |
| 44 |
2020 |
In vitro-invivo extrapolation of metabolic clearance using human liver microsomes: factors showing variability and their normalization. |
--- |
| 45 |
2020 |
Inhibition of human UDP-glucuronosyltransferase enzyme by belinostat: Implications for drug-drug interactions. |
4-MU, DDIs, HDAC, PTCL, TFP, UGTs |
| 46 |
2020 |
Inhibition of UDP-glucuronosyltransferases (UGTs) by polycyclic aromatic hydrocarbons (PAHs) and hydroxy-PAHs (OH-PAHs). |
4-MU, PAHs, UGTs |
| 47 |
2020 |
Inhibition of UDP-glucuronosyltransferases by different furoquinoline alkaloids. |
4-MU, HDIs, Ki, UGTs |
| 48 |
2020 |
Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. |
--- |
| 49 |
2020 |
Per- and polyfluoroalkyl substances exert strong inhibition towards human carboxylesterases. |
BMBT, CES, FD, Ki, PFDoA, PFOcDA, PFTA |
| 50 |
2020 |
Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model |
CsA, DDI, PBK, PET, RSV |
| 51 |
2020 |
The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions. |
DDIs, SFM, SFM, TM |
| 52 |
2020 |
Use of computational toxicology (CompTox) tools to predict in vivo toxicity for risk assessment. |
AED, BMD, CB, CompTox, CPF, HTTK-Pop, LOEL, MOA, PZ |
| 53 |
2020 |
[Approach to drug efficacy and safety assessment based on functions of a human iPSC-derived neuronal network]. |
MEA |
| 54 |
2019 |
Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization. |
HTTK |
| 55 |
2019 |
Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing. |
PBK, tmax |
| 56 |
2019 |
Chemical concentrations in cell culture compartments (C5) - concentration definitions. |
NAM |
| 57 |
2019 |
Considerations for Strategic Use of High-Throughput Transcriptomics Chemical Screening Data in Regulatory Decisions. |
BPACs, HTS, HTTr, NAMs |
| 58 |
2019 |
Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. |
DDI, EPP, fT, OATP |
| 59 |
2019 |
Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro-in vivo extrapolation (IVIVE). |
PBPK, PHH |
| 60 |
2019 |
Incorporating new approach methodologies in toxicity testing and exposure assessment for tiered risk assessment using the RISK21 approach: Case studies on food contact chemicals. |
HTS |
| 61 |
2019 |
Inhibition of UDP-glucuronosyltransferases (UGTs) by bromophenols (BPs). |
4-MU, BPs, DMEs, UGTs |
| 62 |
2019 |
Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples. |
2F-DCK, fu, NPS |
| 63 |
2019 |
Species differences in metabolism of a new antiepileptic drug candidate, DSP-0565 [2-(2'-fluoro[1,1'-biphenyl]-2-yl)acetamide]. |
--- |
| 64 |
2019 |
The potential protein-mediated hepatic uptake: discussion on the molecular interactions between albumin and the hepatocyte cell surface and their implications for the in vitro-to-in vivo extrapolations of hepatic clearance of drugs. |
ALB |
| 65 |
2019 |
The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis. |
MRP, OCTN1, PBPK, PepT1 |
| 66 |
2019 |
Three-dimensional tissue engineering-based Dentin/Pulp tissue analogue as advanced biocompatibility evaluation tool of dental restorative materials. |
--- |
| 67 |
2019 |
Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions. |
fup, PBTK |
| 68 |
2019 |
Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling. |
CL, PK, Vd |
| 69 |
2018 |
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. |
DDI, PBPK |
| 70 |
2018 |
Concentration dependence of in vitro biotransformation rates of hydrophobic organic sunscreen agents in rainbow trout S9 fractions: Implications for bioaccumulation assessment. |
4-MBC, BCFs, EHMC, NADPH, UVFs |
| 71 |
2018 |
Development of a human physiologically based pharmacokinetic (PBPK) model for phthalate (DEHP) and its metabolites: A bottom up modeling approach. |
EDCs, PBPK, QSAR, WHO |
| 72 |
2018 |
Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics. |
HTTK, TK, Vd |
| 73 |
2018 |
Evaluation and Optimization of Pharmacokinetic Models for in Vitro to in Vivo Extrapolation of Estrogenic Activity for Environmental Chemicals. |
EF, ER, LELs, PK, U.S. EPA |
| 74 |
2018 |
Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin InVitro to That in the Presence of Albumin InVivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights. |
ALB, CL, CL, FDM |
| 75 |
2018 |
Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding. |
ALB, CL |
| 76 |
2018 |
In Vitro- in Vivo Extrapolation of Hepatic Metabolism for Different Scenarios - a Toolbox. |
--- |
| 77 |
2018 |
In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds. |
PBTK, YAS, YES |
| 78 |
2018 |
Performance evaluation of the GastroPlusTM software tool for prediction of the toxicokinetic parameters of chemicals. |
AUC, fup, PBPK |
| 79 |
2018 |
Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. |
OATP |
| 80 |
2018 |
The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance. |
--- |
| 81 |
2018 |
Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance. |
CLR |
| 82 |
2017 |
A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. |
BUP, PBPK, SL |
| 83 |
2017 |
An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library. |
fup, HTS, TK |
| 84 |
2017 |
Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different InVitro-InVivo Extrapolation Approaches. |
OATP |
| 85 |
2017 |
Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs). |
Ki, mTOR, UGTs |
| 86 |
2017 |
Inhibitory effects of tanshinones towards the catalytic activity of UDP-glucuronosyltransferases (UGTs). |
4-MU, AUC, HPLC, Ki, UGTs |
| 87 |
2017 |
Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes. |
--- |
| 88 |
2017 |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. |
4betaHC, DDI, PBPK |
| 89 |
2017 |
The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. |
i.v, PBPK |
| 90 |
2016 |
Advancing In Vitro-In Vivo Extrapolations of Mechanism-Specific Toxicity Data Through Toxicokinetic Modeling. |
ECHA |
| 91 |
2016 |
Biotransformation of the fungal neurotoxin Thomitrem A by primary rat hepatocytes. |
--- |
| 92 |
2016 |
Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites. |
COMT, HLC |
| 93 |
2016 |
InVitro-InVivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey. |
CES, PBPK |
| 94 |
2016 |
Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. |
PBPK |
| 95 |
2016 |
Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. |
--- |
| 96 |
2016 |
New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. |
ECCCS, ECM |
| 97 |
2016 |
Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. |
CLR |
| 98 |
2016 |
Pathway Based Toxicology and Fit-for-Purpose Assays. |
--- |
| 99 |
2016 |
Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. |
AS, FIH, PK/PD |
| 100 |
2016 |
Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. |
CLUGT, Def, HLM, MOR, MPPGK, PRO |
|
A Search Service for Abbreviation / Long Form
